Orexigen Therapeutics Inc (OREX.OQ)
OREX.OQ on NASDAQ Stock Exchange Global Select Market
6.04USD
17 May 2013
6.04USD
17 May 2013
Price Change (% chg)
$-0.01 (-0.17%)
$-0.01 (-0.17%)
Prev Close
$6.05
$6.05
Open
$6.10
$6.10
Day's High
$6.12
$6.12
Day's Low
$6.01
$6.01
Volume
246,846
246,846
Avg. Vol
311,475
311,475
52-wk High
$7.73
$7.73
52-wk Low
$3.10
$3.10
About
Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the... (more)
Overall
| Beta: | 1.93 |
| Market Cap (Mil.): | $571.64 |
| Shares Outstanding (Mil.): | 94.64 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| OREX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 53.78 | 35.83 |
| EPS (TTM): | -1.31 | -- | -- |
| ROI: | -86.65 | 1.00 | 18.72 |
| ROE: | -132.46 | 2.10 | 19.54 |
Competitors
| Price | Change | |
|---|---|---|
| Abbott Laboratories (ABT.N) | $36.59 | -0.24 |
| Roche Holding Ltd. (ROG.VX) | CHF247.00 | +1.00 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +5.00 |
| Arena Pharmaceuticals, Inc. (ARNA.OQ) | $7.98 | -0.02 |
| Amylin Pharmaceuticals LLC (AMLN.OQ) | -- | -- |
| Alizyme plc (AZM.L) | -- | -- |
| Athersys, Inc. (ATHX.OQ) | $1.86 | -0.02 |
| NeuroSearch A/S (NEUR.CO) | kr.3.75 | -0.10 |
| Novo Nordisk A/S (NOVOb.CO) | kr.995.00 | -3.00 |
| Sanofi SA (SASY.PA) | €84.50 | -0.12 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Wright Reports
|
$460.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

